https://www.selleckchem.com/pr....oducts/cdk2-inhibito
New antihyperglycemic medications have been proven to have cardiovascular (CV) and renal benefits in type 2 diabetes mellitus (T2DM); however, an evidence-based decision tree in specific clinical scenarios is lacking. Systematic review and meta-analysis of randomized controlled trials (RCTs), with trial sequential analysis (TSA). Randomized controlled trial inclusion criteria were patients with T2DM from 1 of these subgroups elderly, obese, previous atherosclerotic CV disease (ASCVD), previous coronary heart disease (CHD), pre
Me gusta
Comentario
Compartir
